600 related articles for article (PubMed ID: 27993964)
1. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
[TBL] [Abstract][Full Text] [Related]
2. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
3. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
[TBL] [Abstract][Full Text] [Related]
5. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
6. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.
Bachet JB; Blons H; Hammel P; Hariry IE; Portales F; Mineur L; Metges JP; Mulot C; Bourreau C; Cain J; Cros J; Laurent-Puig P
Clin Cancer Res; 2020 Oct; 26(19):5208-5216. PubMed ID: 32605910
[TBL] [Abstract][Full Text] [Related]
9. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
Schwaederlé MC; Patel SP; Husain H; Ikeda M; Lanman RB; Banks KC; Talasaz A; Bazhenova L; Kurzrock R
Clin Cancer Res; 2017 Sep; 23(17):5101-5111. PubMed ID: 28539465
[No Abstract] [Full Text] [Related]
10. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
[No Abstract] [Full Text] [Related]
11. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
13. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
Hata T; Mizuma M; Motoi F; Ohtsuka H; Nakagawa K; Morikawa T; Unno M
J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):815-824. PubMed ID: 36408698
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
[TBL] [Abstract][Full Text] [Related]
17. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.
Uesato Y; Sasahira N; Ozaka M; Sasaki T; Takatsuki M; Zembutsu H
PLoS One; 2020; 15(7):e0235623. PubMed ID: 32614932
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.
Yamaguchi T; Uemura K; Murakami Y; Kondo N; Nakagawa N; Okada K; Seo S; Hiyama E; Takahashi S; Sueda T
Ann Surg Oncol; 2021 Jun; 28(6):3135-3144. PubMed ID: 33128119
[TBL] [Abstract][Full Text] [Related]
20. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]